| Author |
Gérard, C. Tall, M. L. Reymond, E. Boidi Trotti Laleye, D. Hutasse, E. Retière, A-C Dhelens, C. Pirot, F. Pivot, C. |
| Description |
Author Affiliation: Gérard C ( Service pharmaceutique, groupement hospitalier Edouard-Herriot, 5, place d'Arsonval, 69437 Lyon cedex 03, France. Electronic address: cecile.gerard@calydial.org.); Tall ML ( Service pharmaceutique, groupement hospitalier Edouard-Herriot, 5, place d'Arsonval, 69437 Lyon cedex 03, France.); Reymond EB ( Service pharmaceutique, groupement hospitalier Edouard-Herriot, 5, place d'Arsonval, 69437 Lyon cedex 03, France.); Laleye D ( Service pharmaceutique, groupement hospitalier Edouard-Herriot, 5, place d'Arsonval, 69437 Lyon cedex 03, France.); Hutasse E ( Service pharmaceutique, groupement hospitalier Edouard-Herriot, 5, place d'Arsonval, 69437 Lyon cedex 03, France.); Retière AC ( Service pharmaceutique, groupement hospitalier Edouard-Herriot, 5, place d'Arsonval, 69437 Lyon cedex 03, France.); Dhelens C ( Service pharmaceutique, groupement hospitalier Edouard-Herriot, 5, place d'Arsonval, 69437 Lyon cedex 03, France.); Pirot F ( Service pharmaceutique, groupement hospitalier Edouard-Herriot, 5, place d'Arsonval, 69437 Lyon cedex 03, France); Pivot C ( Service pharmaceutique, groupement hospitalier Edouard-Herriot, 5, place d'Arsonval, 69437 Lyon cedex 03, France.) |
| Abstract |
INTRODUCTION: For academic clinical trials, the hospital pharmacy may be required to perform the specific activity of preparing investigational drugs. MATERIAL AND METHODS: With regards to such activity, and in light of the recent changes in the regulatory environment, the main objective of this study was to evaluate whether quality levels and traceability were in compliance with the applicable regulatory standards. In order to do so, two internal audits have been conducted, the first on the compliance of operations with existing regulatory standards and the second on the quality of traceability of the operations. RESULTS: The proportion of academic clinical trials is constantly growing and currently represents 41% of the total clinical trials in the establishment. An average of 29,000 therapeutic units of investigational drugs are prepared each year (84% under the form of capsules). An overall conformity level of 75% and 88% has been identified in the aforementioned audits, respectively. Such audits have also allowed for the identification of weaknesses in current practices as well as potential improvement areas to achieve better compliance. DISCUSSION: The hospital pharmacy can provide expertise for the preparation of specific dosage or drugs that are not available on the market. It also can be involved for the conception of appropriated packaging function of the study design. CONCLUSION: Results of audits encourage us to continue this activity with a satisfactory level of quality in accordance with the necessary requirements to ensure the safety of patients and the quality of clinical trials conducted. |
